Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results

Organ-sparing therapy for early-stage I/IIA rectal cancer is intended to avoid functional disturbances or a permanent ostomy associated with total mesorectal excision (TME). The objective of this phase II trial was to determine the outcomes and organ-sparing rate of patients with early-stage rectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennecke, Hagen F., O'Callaghan, Chris J., Loree, Jonathan M., Moloo, Hussein, Auer, Rebecca, Jonker, Derek J., Raval, Manoj, Musselman, Reilly, Ma, Grace, Caycedo-Marulanda, Antonio, Simianu, Vlad V., Patel, Sunil, Pitre, Lacey D., Helewa, Ramzi, Gordon, Vallerie L., Neumann, Katerina, Nimeiri, Halla, Sherry, Max, Tu, Dongsheng, Brown, Carl J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839227/
https://www.ncbi.nlm.nih.gov/pubmed/35981270
http://dx.doi.org/10.1200/JCO.22.00184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839227/
https://www.ncbi.nlm.nih.gov/pubmed/35981270
http://dx.doi.org/10.1200/JCO.22.00184

Ejemplares similares